Gamida Cell Ltd (GMDA)
US Market

Gamida Cell Stock Price & Analysis


GMDA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.47 - $4.72
Previous Close$1.59
Average Volume (3M)647.44K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$55.06M
Total Debt (Recent Filing)$7.08M
P/E Ratio-1.1
Next EarningsNov 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.50
Shares Outstanding59,977,188
Standard Deviation0.24
10 Day Avg. Volume773,395
30 Day Avg. Volume647,437
P/B Ratio12.15
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside758.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Gamida Cell’s price range in the past 12 months?
Gamida Cell lowest stock price was $1.47 and its highest was $4.72 in the past 12 months.
    What is Gamida Cell’s market cap?
    Currently, no data Available
    When is Gamida Cell’s upcoming earnings report date?
    Gamida Cell’s upcoming earnings report date is Nov 15, 2022 which is in 42 days.
      How were Gamida Cell’s earnings last quarter?
      Gamida Cell released its earnings results on Aug 15, 2022. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.292 by -$0.018.
        Is Gamida Cell overvalued?
        According to Wall Street analysts Gamida Cell’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Gamida Cell pay dividends?
          Gamida Cell does not currently pay dividends.
          What is Gamida Cell’s EPS estimate?
          Gamida Cell’s EPS estimate is -$0.31.
            How many shares outstanding does Gamida Cell have?
            Gamida Cell has 72,882,190 shares outstanding.
              What happened to Gamida Cell’s price movement after its last earnings report?
              Gamida Cell reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.292. Following the earnings report the stock price went up 7.309%.
                Which hedge fund is a major shareholder of Gamida Cell?
                Among the largest hedge funds holding Gamida Cell’s share is Highbridge Capital Management LLC. It holds Gamida Cell’s shares valued at 2M.


                  Gamida Cell Stock Analysis

                  Smart ScoreOutperform
                  The Gamida Cell stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Gamida Cell Ltd

                  Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

                  Similar Stocks
                  Price & Change
                  Phasebio Pharmaceuticals
                  Urogen Pharma
                  Enlivex Therapeutics
                  Collplant Holdings

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis